BMJ Open

Mini-sternotomy versus conventional sternotomy for aortic valve replacement: a randomised controlled trial

Helen C Hancock ⓘ ,[1] Rebecca H Maier ⓘ ,[1] Adetayo Kasim,[2] James Mason,[3] Gavin Murphy,[4] Andrew Goodwin,[5] W Andrew Owens ⓘ ,[5] Enoch Akowuah ⓘ [5]

Correspondence to
Enoch Akowuah;
enoch.akowuah@nhs.net

ABSTRACT

Objective To compare clinical and health economic outcomes after manubrium-limited mini-sternotomy (intervention) and conventional median sternotomy (usual care).

Design A single-blind, randomised controlled trial.

Setting Single centre UK National Health Service tertiary hospital.

Participants Adult patients undergoing aortic valve replacement (AVR) surgery.

Interventions Intervention was manubrium-limited mini-sternotomy performed using a 5–7 cm midline incision. Usual care was median sternotomy performed using a midline incision from the sternal notch to the xiphisternum.

Primary and secondary outcome measures The primary outcome was the proportion of patients who received a red cell transfusion postoperatively and within 7 days of index surgery. Secondary outcomes included proportion of patients receiving a non-red cell blood component transfusion and number of units transfused within 7 days and during index hospital stay, quality of life and cost-effectiveness analyses.

Results 270 patients were randomised, received surgery and contributed to the intention to treat analysis. No difference between mini and conventional sternotomy in red-cell transfusion within 7 days was found; 23/135 patients in each arm received a transfusion, OR 1.0 (95% CI 0.5 to 2.0) and risk difference 0.0 (95% CI −0.1 to 0.1). Mini-sternotomy reduced chest drain losses (mean 181.6 mL (SD 138.7) vs conventional, mean 306·9 mL (SD 348.6)); this did not reduce red-cell transfusions. Mean valve size and postoperative valve function were comparable between mini-sternotomy and conventional groups; 23 mm vs 24 mm and 6/134 moderate or severe aortic regurgitation vs 3/130, respectively. Mini-sternotomy resulted in longer bypass (82.7 min (SD 23.5) vs 59.6 min (SD 15.1)) and cross-clamp times (64.1 min (SD 17.1) vs 46·3 min (SD 10.7)). Conventional sternotomy was more cost-effective with only a 5.8% probability of mini-sternotomy being cost-effective at a willingness to pay of £20 000/QALY (Quality Adjusted Life Years).

Conclusions AVR via mini-sternotomy did not reduce red blood cell transfusion within 7 days following surgery when compared with conventional sternotomy.

Trial registration number ISRCTN29567910; Results.

Strengths and limitations of this study

► Large proportion of eligible patients recruited, and all patient randomised contributed to the primary outcome.
► Clear protocols for transfusion of blood and blood products with high adherence throughout the trial.
► Patients were blinded to group allocation until 2 days following index surgery, reducing the likelihood of bias.
► First randomised trial to perform detailed health economic evaluation of minimally invasive versus conventional sternotomy.
► The trial was undertaken by three experienced minimally invasive surgeons who were expert at both techniques.

OBJECTIVES

Aortic valve replacement (AVR) for severe symptomatic valvular disease is one of the most common cardiac surgical procedures performed worldwide. The current joint guidelines of the American College of Cardiology and American Heart Association and the current European Society of Cardiology guidelines for the management of aortic valve disease state that surgical AVR is recommended for symptomatic patients with severe aortic stenosis and asymptomatic patients with severe aortic stenosis who meet an indication for AVR when surgical risk is low or intermediate.[1]

In the UK, the National Adult Cardiac Surgery Audit published by National Institute for Cardiac Outcome Reporting reported 13 027 procedures for aortic valve disease in the UK from April 2018 to March 2019.[2] Outcomes are generally excellent with in-hospital observed mortality in the UK of 1.5% for first-time elective procedures.[3] In low-risk patients with a EuroSCORE 2 of less than 4, a mortality of less than 0.7% was observed in over 15 000 patients undergoing AVR surgery in the UK between 2016 and 2019.[2]

These results are not observed in all patients; in high-risk groups, conventional surgery risks perioperative organ injury and prolonged recovery, with death in up to 31% of patients within 1 year.[4] Minimally invasive surgery combines the durability of surgical repair with reductions in surgical trauma that should reduce perioperative morbidity. Observational analyses demonstrating reductions in morbidity and resource use[5 6] may be confounded by multiple sources of bias and are at odds with limited evidence from randomised controlled trials (RCTs) that have not shown improved outcomes.[7] This uncertainty is reflected by variations in uptake internationally.[8–10]

The move towards minimally invasive surgery is also driven by patient perceptions of pain reduction and rapid recovery. However, minimally invasive cardiac surgery is not without risks; limiting access to the heart can result in technically suboptimal surgery, including concern about the size of the prosthesis that can be inserted and paravalvular leak rates.

This trial evaluated manubrium-limited mini-sternotomy versus conventional sternotomy for aortic valve replacement (MAVRIC). We hypothesised that mini-sternotomy would reduce red cell transfusion rates, a contemporary marker of surgical trauma and indicator of adverse outcomes[11]; this has been contested,[12] though the evidence is not conclusive.[13] An embedded cost-effectiveness analysis evaluated whether the intervention was cost effective in a UK National Health Service (NHS) setting.

PATIENTS AND METHODS
Trial design
MAVRIC was a single-centre, single-blind, RCT comparing AVR via manubrium-limited mini-sternotomy group (intervention) and AVR via conventional sternotomy group (usual care). An NHS Research Ethics Committee approved the trial, which was conducted in accordance with the principles of the International Conference on Harmonisation of Good Clinical Practice.[14] South Tees Hospitals NHS Foundation Trust was the sponsor and recruiting centre.

Patient and public involvement
In designing the study, we asked patients their view on what factors may affect whether they took part in the study. This was done in an outpatient setting and via a postal questionnaire. They felt expertise was important. Most patients felt that although the cosmetic benefit of the minimally invasive approach was appealing, they expected some clinical benefit from minimally invasive surgery as well. Importantly, most patients said they would accept being blind to the type of surgery they had received for 48 hours after the procedure.

Participants
Patients were eligible if they were aged 18 years or over; required first-time, non-emergency, isolated AVR surgery and were willing to provide written informed consent. Full details of the eligibility criteria are in the online supplemental material.

Randomisation
Eligible patients were randomised by members of the research team using a 24-hour, central, secure, web-based randomisation system with concealed allocation, managed by the Clinical Trials Unit; randomisation was in a 1:1 ratio between mini and conventional sternotomy and stratified by baseline logistic EuroSCORE and preoperative haemoglobin (Hb).

Interventions
Manubrium-limited mini-sternotomy was performed using a 5–7 cm midline skin incision dividing the manubrium from the sternal notch to 1 cm below the manubrium–sternal junction. Cardiopulmonary bypass was established with an ascending aortic cannula and percutaneous femoral venous cannulation. Conventional median sternotomy was performed using a midline incision from the sternal notch to the xiphisternum. Key aspects of anaesthesia were standardised and are detailed in the protocol.[15]

Blinding
All patients were blinded to the type of sternotomy received until after their day 2 quality of life and pain assessments. All patients had trial-specific opaque dressings applied to their sternal wound and groin before leaving theatre.

Transfusion protocol
The postoperative period, and trial protocol in relation to red cell and non-red cell transfusion, began on admission to the cardiothoracic intensive care unit; it specified that patients should receive a red cell transfusion if their Hb dropped below 80 g/L or were bleeding by 400 mL/hour or more, or were bleeding 100 mL/hour or more for 4 or more hours with an Hb equal to or greater than 80 g/L or had blood loss with haemodynamic instability irrespective of thromboelastography (TEG) and/or clotting profile results. One unit of red cells was transfused and Hb level checked before transfusing another unit.

Participants received a non-red cell transfusion if both of the following criteria were met: bleeding defined by 400 mL/hour or more or blood loss of 100 mL/hour or more for 4 hours or more; TEG or coagulation-guided transfusion indicated.

Outcomes
All outcomes were measured from index surgery.

Primary outcome
The primary outcome was the proportion of patients who received a red cell transfusion postoperatively and within 7 days of index surgery.

Secondary outcomes

► Proportion of patients receiving a red cell transfusion and number of units transfused within 7 days and during index hospital stay.
► Proportion of patients receiving a non-red cell blood component transfusion and number of units transfused within 7 days and during index hospital stay.
► Volume in chest drains at 6 and 12 hours and drain removal.
► Degree of aortic regurgitation using echocardiogram within 6 weeks.
► Re-operation rates.
► Conversion to conventional AVR during surgery.
► Changes in lung function at 4 days and 6 weeks.
► Quality of life EuroQol (EQ-5D-3L, EQ-VAS) at 2 days, 6 and 12 weeks.
► Time patients are deemed 'fit for discharge'.
► Healthcare utilisation to 12 weeks.
► Cost and cost-effectiveness analyses.
► Adverse events to 12 weeks.

Statistical analysis

Audit data had indicated 30% of patients undergoing AVR via conventional sternotomy (15 of 50 patients) received a red cell transfusion compared with 13% of patients (8 of 60 patients) undergoing AVR via mini-sternotomy. Using Fisher's exact test, 90% power, 5% alpha, we estimated that 260 patients would be required to detect a 17% reduction in the proportion of patients requiring a red cell transfusion (13% compared with 30%), using a two-sided test. Allowing for loss to follow-up, the sample size was increased to 270.

The primary analysis was based on intention-to-treat principles, in accordance with a pre-specified statistical analysis plan.

The primary efficacy analysis was based on a logistic regression model with only group (minimally invasive and conventional) and stratifying factors (baseline logistic EuroSCORE and Hb) as the predictors. ORs and their associated 95% CIs are reported in the primary analysis. Sensitivity analysis using alternating logistic regression was performed for the primary endpoint to sensitise for surgeon effects; the odds of receiving a red cell transfusion for two patients treated by the same surgeon was compared with two patients treated by different surgeons.

All analyses of secondary continuous efficacy endpoints at single time points were based on linear models where, if appropriate, a log normal model was fitted to sensitise the linearity assumption. Longitudinal analysis was performed for all endpoints with repeated data over time to investigate changes in trends over the trial period. The trial period was defined as baseline, up to 7 days (postoperative period), 6-week follow-up and 12-week follow-up. All analyses of binary endpoints at a single time point were based on logistic regression. Generalised estimating equation was used to analyse repeated binary data per patient to account for intrapatient correlation.

Further exploratory analysis was conducted to investigate the association between the treatment group and other


Figure 1 Consolidated Standards of Reporting Trials diagram. Flow of participants through trial.

clinical factors. All analyses were performed using R V.3.3.3 (The R Foundation) and SAS V.9.4 (SAS Institute).

Economic evaluation

A prospective economic evaluation applying an NHS perspective, following National Institute for Health and Care Excellence reference case guidance,[16] was employed. Healthcare utilisation was captured up to 3 months following discharge from index surgery. Resource use was valued in 2016 pounds sterling using national sources,[17 18] and where necessary, local microcosting (£1=US$1.50). Resources included surgery, transfusions, length of hospital stay (by level of care), complications and further surgery and community care following discharge.

Mechanisms of missingness within the data were explored and multiple imputation methods were applied to impute missing data and minimise bias, using chained equations and predictive mean matching. Imputation sets were analysed within a bivariate analysis of costs and QALYs to generate incremental within-trial cost per QALY estimates and credible intervals. Findings were presented on the incremental cost-effectiveness ratio (ICER) plane and with cost-effectiveness acceptability curves, using the net monetary benefit approach.

Imputation was conducted according to good practice guidance.[19 20] Multiple imputation provides unbiased estimates of treatment effect if data are missing at random and the missingness process is adequately characterised: this assumption was explored in the data, for example, by using logistic regression for missingness of costs and QALYs against baseline variables.[21] A regression model was used to generate multiple imputed datasets (or 'draws') for individual treatment groups, where missing values were predicted drawing on predictive covariates. Outcome measures and costs (at each time point) contributed as predictors and imputed variables. Each draw provided a complete dataset, reflecting the distributions and correlations between variables. Predictive mean matching drawn from the five nearest neighbours (knn=5) was used to enhance the plausibility and robustness of imputed values; normality was not assumed. The imputation model used fully conditional (MCMC) methods. Draws were analysed using bivariate regression (see below) within the Stata MI framework, capturing within and between variances for imputed samples.[22] After examining the fraction of missing information from finite imputation sampling, 20 draws were taken in the final imputation model.

RESULTS
Trial population

MAVRIC recruited to time and target; 313 patients were considered for the trial; 274 patients consented between 20 March 2014 and 25 July 2016. The analysis population was 270 eligible patients; 135 allocated to the AVR via mini-sternotomy group and 135 allocated to the AVR via conventional sternotomy group (figure 1).

All 270 patients underwent surgery. Sixteen patients required cross-over from minimally invasive to a conventional sternotomy due to anaesthetic emergency (n=2), difficulties due to vascular access (n=9) and intraoperative complications (n=5); further details and the number of operations performed by surgeon are in the online supplemental material.

Baseline characteristics were similar between groups (table 1).

Primary outcome

There was no difference between groups in relation to the primary outcome (table 2). The proportion of patients receiving a red cell transfusion was 23 of 135 in both groups, OR 1.0 (95% CI 0.5 to 2.0; p=0.9052) and risk difference of 0.0 (95% CI –0.1 to 0.1; p=0.9999).

Secondary outcomes
Red cell and non-red cell transfusion

There was no significant difference between groups with respect to any red cell transfusion at discharge (table 2). There was no difference between groups in Hb from baseline to 4 days following index surgery (online supplemental material). There was a statistically significant difference in the proportion of patients receiving any non-red cell transfusion within 7 days of surgery; mini 6/135 vs conventional 18/135, OR 0.3 (95% CI 0.1 to 0.8; p=00137) (table 3).

Cross-clamp time and cardiopulmonary bypass time

Mini-sternotomy resulted in longer cardio pulmonary bypass times; mini group 82.7 min (SD 23.5), conventional 59.6 min (SD 15.1). Aortic cross-clamp times were also longer; mini group 64.1 min (SD 17.1), conventional 46.3 min (SD 10.7) (table 4).

Chest drain losses

Mini-sternotomy resulted in a 40·8% reduction in chest drain losses at 12 hours, the mini group mean was 181.6 mL (SD 138.7), conventional group mean was 306.9 mL (SD 348.6); the mean difference was –127.7 mL (95% CI –191.7 to –63.8, p=0.0001). At drain removal, mean difference was –145.3 mL (95% CI –218.1 to–72.3; p=0.0001) (table 4).

Ventilation time

Ventilation time between the groups was similar; 9·6 hours (SD 5.6) in the mini group and 9.8 hours (SD 6.9) in the conventional (table 4).

Intensive care unit length of stay

There was no difference in intensive care unit length of stay between groups (online supplemental material).

Postoperative pain

There was no difference in pain scores between groups; analgesic use is also included to assist interpretation (online supplemental material).

Lung function

There was no difference between groups in lung function at baseline. At 4 days post surgery, mean forced expiratory volume in 1 s (FEV_1) 1123 mL (SD 433) and forced vital capacity (FVC) 1479 mL (SD 583) were significantly reduced in the mini group, compared with the conventional; FEV_1 1321 (SD 524), FVC 1698 (SD 707). Mean

differences for FEV_1 and FVC were statistically significant at 4 days post surgery; −171 mL (95% CI −265 to −77; p=0.0004) and −130 mL (95% CI −269 to 0; p=0.0498), respectively, after adjusting for baseline FEV_1, FVC and randomisation factors (online supplemental material).

Hospital length of stay

The mean time to patients being fit for hospital discharge following index surgery was similar between groups. The mean postoperative hospital length of stay was 7.4 (SD 7.5, range 3–79) in the mini group, and 6.3 days (SD 3.2, range 3–31) in the conventional (online supplemental material).

Postoperative valve function

The distribution of valve types and valve sizes by group was similar; mean valve size inserted was 23 mm in the mini group and 24 mm in the conventional (table 5, figures 2 and 3). Over 70% of patients in each group received a tissue valve, over 25% received a mechanical valve and 2%–3% received a sutureless tissue valve.

Postoperative transthoracic echo showed a similar decrease in mean aortic valve gradient in both groups to 16 mm Hg; peak gradient decreased to 30 mm Hg in both groups (table 5); 6/134 patients had moderate or severe aortic regurgitation in the mini group compared with 3/130 in the conventional (table 5). Only two patients in the trial, one in each arm, suffered a paravalvular leak; both were severe. One of these patients, in the mini sternotomy arm, had a sutureless valve prosthesis. Seven further patients had moderate regurgitation; these were all intravalvular leaks. Transoesophageal echo was performed in all patients prior to leaving the operating theatre.

Adverse events

There were no in-hospital deaths in either group. At 12 weeks follow-up, there were four deaths; two in each arm of the study. Adverse events in each group were broadly similar and within acceptable clinical limits. By 12 weeks, 4/135 patients in the mini-sternotomy group and 1/135 in the conventional group had suffered a stroke (defined as a persistent neurological deficit). Atrial arrhythmias were identified in 61/135 patients in the mini group and 51/135 in the conventional. By 12 weeks, 11/135 patients in the mini group and 3/135 patients in the conventional had a sternal wound infection (online supplemental material).

Quality of life, costs and cost-effectiveness

Costs during the index admission were significantly greater for the mini group (mini-conventional: mean difference £1140; 95% CI 303 to 1977), primarily reflecting the additional cost of theatre time (online supplemental material). Overall costs were not significantly different (mini-conventional: mean difference £746; 95% CI −245 to 1737). There was no significant difference in quality of life between groups up to 12 weeks (mini-conventional: mean difference area under curve −0.009 QALYs; 95% CI 0.020 to 0.002). Although differences

Table 1	Baseline characteristics of participants by group	
	Mini-sternotomy group (n=135)	**Conventional sternotomy group (n=135)**
Baseline characteristics		
Age (years)		
Mean±SD	69.3±9.3	68.7±8.4
Range	43–85	39–88
Gender n (%)		
Male	78 (57.8)	87 (64.4)
Female	57 (42.2)	48 (35.6)
Ethnicity n (%)		
White British	135 (100)	135 (100)
Body mass index (kg/m²)		
Mean±SD	30.5±5.6	30.4±6.1
Range (min–max)	19.0–45.4	19.3–52.0
EuroSCORE: Mean±SD (min–max)		
Logistic	5.2±3.5 (1.5–29.5)	5.1±3.5 (1.5–21.0)
II–mean	1.5±1.1 (0.5–10.2)	1.5±1.2 (0.5–10.0)
Diagnosis echocardiogram: n (%)		
Regurgitation	3 (2.2)	8 (5.9)
Stenosis	132 (97.8)	127 (94.1)
NYHA class: n (%)		
I	24 (17.8)	18 (13.3)
II	68 (50.4)	66 (48.9)
III	40 (29.6)	46 (34.1)
IV	3 (2.2)	5 (3.7)
*Haemoglobin prior to randomisation: g/dL		
Mean±SD	137.9±14.3	137.1±16.1
Range (min–max)	97–173	90–175
Surgery type: n (%)		
Elective	111 (82.2)	112 (82.6)
In-house urgent	24 (17.8)	23 (17.4)

*One patient had a baseline haemoglobin (Hb) of 95 g/L at randomisation, which had fallen to 83 immediately prior to surgery. This Hb drop was not identified until after surgery and the patient continued in the trial with their data included in the analyses based on the intention-to-treat principle.

Table 2 The number and proportion of patients receiving a red cell transfusion*, and the number of units received, to 7 days and to discharge following index surgery, by group

	Mini-sternotomy group	Conventional sternotomy group	OR (95% CI; p value)	Risk difference (95% CI; p value)
Red cell transfusions				
Postoperatively to 7 days number of patients (%)	23/135 (17.0)	23/135 (17.0)	1.0 (0.5 to 2.0; 0.9052)	0.0 (−0.1 to 0.1; 0.9999)
Postoperatively to discharge number of patients (%)	34/135 (25.2)	29/135 (21.5)	1.4 (0.7 to 2.7)	
Red cell units—postoperatively to 7 days				
Number of patients	23/135	23/135		
Mean±SD	1.6±0.7	2.3±1.7		
Range (min–max)	1–3	1–9		
Red cell units—postoperatively to discharge				
Number of patients	34/135	29/135		
Mean±SD	2.5±2.5	2.6±2.0		
Range (min–max)	1–13	1–11		

*Reprinted from Hancock et al,[28] with permission from Elsevier.

in costs and quality of life were not individually significant, the bivariate cost–QALY distribution (combining these two) suggests conventional surgery might be more cost-effective (figure 4). In the base-case model, mini was dominated by conventional surgery (due to greater cost and less benefit), with only a 5.8% probability of being cost-effective at a willingness to pay of £20 000/QALY (table 6).

Sensitivity and subgroup analyses
There was no significant surgeon effect; the odds of receiving a red cell transfusion for two patients treated by the same surgeon compared with two patients treated by different surgeons was 1·2 (95% CI 0.9 to 1.6; p=0.1379).

Protocol deviations in respect of cell tranfusions did not affect the results of the primary analysis; excluding these patients produced the same results as those from the intention-to-treat analysis.

DISCUSSION
Main findings
Mini-sternotomy was not superior to conventional sternotomy with respect to red cell transfusion requirements within 7 days of surgery. Analysis of secondary endpoints showed a statistically significant difference in transfusion volumes of non-red cell blood components. Aortic

Table 3 The number and proportion of patients receiving a non-red cell transfusion, and the number of units received, to 7 days and to discharge following index surgery, by group

	Mini-sternotomy group	Conventional sternotomy group	OR (95% CI p value)
Non-red cell transfusions			
Postoperatively to 7 days number of patients (%)	6/135 (4.4)	18/135 (13.3)	0.3 (0.1 to 0.8; 0.0137)
Postoperatively to discharge number of patients (%)	13/135 (9.6)	21/135 (15.6)	0.6 (0.3 to 1.2)
Non-red cell component units—postoperatively to 7 days			
Number of patients	6	18	
Mean±SD	3.2±0.9	4.6±1.6	
Range (min–max)	2–5	1–7	
Non-red blood cell units—postoperatively to discharge			
Number of patients	13	21	
Mean±SD	4.8±2.3	4.9±2.3	
Range (min–max)	1–8	1–12	
Non-red cell component transfusions			
Postoperatively to 7 days number of patients (%)	6 (4.4)	18 (13.3)	0.3 (0.1 to 0.8)
Postoperatively to discharge number of patients (%)	13 (9.6)	21 (15.6)	0.6 (0.3 to 1.2)

Table 4 Outcomes during index hospital stay for cardiopulmonary bypass and aortic cross-clamp times and drain losses

	Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)	Mean difference (95% CI; p value)
Cardio pulmonary bypass time (min)			
Mean±SD	82.7±23.5	59.6±15.1	
Range (min–max)	41.0–199	37.0–170.0	
Aortic cross-clamp time (min)			
Mean±SD	64.1±17.1	46.3±10.7	
Range (min–max)	32.0–132.0	32.0–97.0	
Drain losses at 12 hours			
Mean±SD	181.6±138.7	306.9±348.6	−127.7 (−191.7 to −63.8; 0·0001)
Range (min–max)	25–925	25–3000	
Drain losses at drain removal			
Mean±SD	251.7±198.4	393.7±378.7	−145.3 (−218.1 to −72.3; 0·0001)
Range (min–max)	25–1425	50–3000	

valve size and postoperative function were comparable in the two groups. Mini-sternotomy resulted in a relative reduction in chest drain losses; however, higher blood loss in the conventional group did not translate into red cell transfusions. Mini patients had substantially longer bypass and cross-clamp times and worse lung function at 4 days post surgery. Lung function at 12 weeks and adverse event rates were otherwise not different between groups. Conventional sternotomy was found to be more cost-effective. MAVRIC findings contradict those from other trials that pre-date it.[23 24] Two 100 patient RCTs published since MAVRIC and the systematic review do not alter the discussion.[25 26] Both found no difference in major clinical outcomes and findings relating to shorter hospital stay in mini-sternotomy; a reduction in bleeding through chest drains and mean difference in EQ-5D scores at baseline and at 6 weeks[25] are consistent with MAVRIC findings.

Strengths and limitations

This is the largest single trial to have compared minimally invasive sternotomy to conventional median sternotomy for AVR. A recent Cochrane review identified 511 patients from 7 previous RCTs.[7] In MAVRIC, the mini-sternotomy technique divided only the manubrium and is therefore less invasive than other minimally invasive techniques. The trial was undertaken by three experienced minimally invasive surgeons who were expert at both techniques. Patients were blinded to group allocation until 2 days following index surgery, reducing the likelihood of bias. The trial recruited a significant proportion of eligible patients; 274/313 (86%), with few requiring conversion to conventional sternotomy, increasing the likelihood that the trial findings are generalisable. A further strength was the detailed health economic evaluation; this has not been performed previously.

The trial had some limitations, including the single centre design. This will tend to have biased treatment effect estimates away from the null, which is at odds with

our observed effect. There were no significant levels of protocol non-adherence, with no effect on the main trial finding. The event rate for the primary outcome was much lower than expected at 17%; nationally red cell transfusion rates following valve surgery are 46·4%.[27] In our pre-trial audit conducted over 5 years, ending 2009, 30% of mini-sternotomy patients received a red cell transfusion. We attribute the observed transfusion rate in MAVRIC to the restrictive red cell transfusion threshold applied; this followed evidence at the time of trial design. The consultant (expert) led nature of the trial interventions is also likely to have reduced the need for transfusions postoperatively and to have biased trial results towards the null.

Clinical importance

MAVRIC contributes important evidence to the minimally invasive AVR evidence base, summarised in a Cochrane review.[7] MAVRIC demonstrated longer cross-clamp and bypass times with the manubrium-limited mini-sternotomy, attributed to known differences between the interventions. Minimally invasive techniques in MAVRIC required a number of surgical steps to be performed with the aortic clamp in place (drain insertion and pacing wire insertion, for example), meaning cross-clamp and bypass were longer. This is not an absolute requirement in other minimally invasive approaches; for example, where the incision is extended into the body of the sternum or where rapid deployment valves are used, there are no differences in cross-clamp and bypass times.[7]

The size of MAVRIC and event rate prevents formal comparison of adverse events between the groups, of note is the difference in stroke rate; this would benefit from exploration in a future trial.

The cost-effectiveness plane indicates that conventional surgery is less costly and more beneficial than minimally invasive surgery; contact with healthcare professionals was greater in the mini group, although there was no clear pattern of use. Wide CIs mean that differences are

Table 5 Outcomes during index hospital stay for valve size and type, and for valve function and regurgitation to 6 weeks by group

Valve characteristics	Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)	Mean difference (95% CI; p value)
Valve size: mm			
19–21 mm n (%)	40 (29.6)	38 (28.1)	
23–25 mm n (%)	84 (62.2)	80 (59.3)	
27–29 mm n (%)	11 (8.2)	17 (12.6)	
Mean±SD	23.1±2.1	23.6±2.5	
Range (min–max)	19.0–29.0	19.0–31.0	
Valve type: n (%)			
Biological and sutureless	4 (3.0)	3 (2.2)	
Biological prosthesis	96 (71.1)	98 (72.6)	
Mechanical prosthesis	35 (25.9)	34 (25.2)	
Valve function			
Mean gradient			
Baseline			
n	111*	110*	
Mean±SD	47.9±15.7	47.7±20.2	0.2 (−4.6 to 5.0)
Min–max	10–93	8–110	
6 weeks			
n	120*	126*	
Mean±SD	15.7±5.5	15.7±5.8	0.5†(−1.0 to 2.1)
Min–max	6–33	4–34	
Peak gradient			
Baseline			
n	125*	124*	
Mean±SD	82.3±25.9	77.1±29.1	5.2 (−1.7 to 2.3)
Min–max	16–152	8–173	
6 weeks			
n	130*	130*	
Mean±SD	29.9±10.5	29.7±10.8	−0.3† (−2.9 to 2.3)
Min–max	12–62	11–61	
Aortic valve regurgitation			
Nil/trivial			
n/n (%)	109/134* (81.3)	109/130* (83.8)	218/264 (82.6)
Mild			
n/n (%)	19/134* (14.2)	18/130* (13.9)	37/264 (14.0)
Moderate			
n/n (%)	5/134* (3.7)	2/130* (1.5)	7/264 (2.7)
Severe			
n/n (%)	1/134* (0.8)	1/130* (0.8)	2/264 (0.8)

*It was not possible to quantify valve function in all patients.
†After adjusting for randomisation factors and baseline data.

imprecise. MAVRIC does not support the use of funds to expand AVR via manubrium-limited mini-sternotomy practice.


**Figure 2** Valve size distribution: mini-sternotomy group.

**Figure 3** Valve size distribution: conventional sternotomy group.

Figure 4 Cost-effectiveness plane, cost/QALY (£): mini-sternotomy versus conventional surgery.

MAVRIC, the world's largest RCT at low risk of bias, found no additional clinical benefit, in terms of red blood cell transfusion rates of minimally invasive AVR. Results are in agreement with the findings of a Cochrane review of trials that have evaluated mini-sternotomy AVR.[7] This information should be disseminated to patients,

Table 6 Cost-effectiveness, cost/QALY (£): mini-sternotomy versus conventional surgery

Model	Incremental cost (95% CI)	Incremental QALYs (95% CI)	ICER (95% CI)	P value*	P value†
Multiple imputation, covariate adjusted‡	508(−202 to 1217)	−0.007(−0.016 to 0.002)	Dominated§	0.058	0.052
Multiple imputation, unadjusted	859(−116 to 1833)	−0.008(−0.018 to 0.003)	Dominated	0.023	0.021
Complete case, covariate adjusted‡	630(25 to 1224)	−0.007(−0.016 to 0.002)	Dominated	0.013	0.011
Complete case, unadjusted	544(−99 to 1142)	−0.009(−0.02 to 0.002)	Dominated	0.027	0.022

*Probability cost-effective or net monetary benefit if willing to pay £20 000/QALY.
†Probability cost-effective or net monetary benefit if willing to pay £30 000/QALY.
‡Regression estimates adjusted for trial stratifying covariates and baseline EQ-5D.
§Dominance indicates average costs were less and average benefit greater for conventional surgery.

clinicians and commissioners to inform decisions about AVR surgery including commissioning.

Author affiliations
[1]Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK
[2]Wolfson Research Institute for Health and Wellbeing, Durham University, Stockton-on-Tees, Durham, UK
[3]Warwick Medical School, University of Warwick, Coventry, UK
[4]Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Unit in Cardiovascular Medicine, University of Leicester, Leicester, UK
[5]Department of Cardiothoracic Surgery, James Cook Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK

ORCID iDs
Helen C Hancock http://orcid.org/0000-0002-1494-8551
Rebecca H Maier http://orcid.org/0000-0002-7350-3288
W Andrew Owens http://orcid.org/0000-0001-9836-9209
Enoch Akowuah http://orcid.org/0000-0002-2429-3579

REFERENCES
1 Matiasz R, Rigolin VH. 2017 focused update for management of patients with valvular heart disease: summary of new recommendations. *J Am Heart Assoc* 2018.
2 National adult cardiac surgery audit 2020 summary report 2016.
3 Blue Book Online. The Society for Cardiothoracic Surgery in Great Britain & Ireland. Available: http://bluebook.scts.org/# [Accessed 23 Jul 2018].
4 Leontyev S, Walther T, Borger MA, *et al*. Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. *Ann Thorac Surg* 2009;87:1440–5.
5 Phan K, Xie A, Di Eusanio M, *et al*. The Collaborative Research (CORE) group. meta-analysis of minimally invasive versus conventional sternotomy for aortic valve replacement. *Ann Thorac Surg* 2014;98:1499–511.
6 Ghanta RK, Lapar DJ, Kern JA, *et al*. Minimally invasive aortic valve replacement provides equivalent outcomes at reduced cost compared with conventional aortic valve replacement: a real-world multi-institutional analysis. *J Thorac Cardiovasc Surg* 2015;149:1060–5.
7 Kirmani BH, Jones SG, Malaisrie SC, *et al*. Limited versus full sternotomy for aortic valve replacement. *Cochrane Database Syst Rev* 2017;4:CD011793.
8 Fujita B, Ensminger S, Bauer T, *et al*. Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42 776 patients. *Eur J Cardiothorac Surg* 2018;53:552–9.
9 Lehmann S, Merk DR, Etz CD, *et al*. Minimally invasive aortic valve replacement: the Leipzig experience. *Ann Cardiothorac Surg* 2015;4:49–56.
10 Johnston DR, Roselli EE. Minimally invasive aortic valve surgery: Cleveland clinic experience. *Ann Cardiothorac Surg* 2015;4:140–7.
11 Patel NN, Avlonitis VS, Jones HE, *et al*. Indications for red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis. *Lancet Haematol* 2015;2:e543–53.
12 Chen Q-H, Wang H-L, Liu L, *et al*. Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. *Crit Care* 2018;22:142.

13 Pagano D, Milojevic M, Meestersa MI. The task force on patient blood management for adult cardiac surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA). EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. *Eur J Cardio-Thorac Surg* 2018;53:79–111.

14 Dixon JR. The International Conference on Harmonization Good Clinical Practice guideline. *Qual Assur* 1998;6:65–74.

15 Akowuah E, Goodwin AT, Owens WA, *et al*. Manubrium-limited ministernotomy versus conventional sternotomy for aortic valve replacement (MAVRIC): study protocol for a randomised controlled trial. *Trials* 2017;18:46.

16 NICE. *Guide to the methods of technology appraisal*. London: National Institute for Health and Care Excellence, 2013.

17 NHS reference costs 2015-16. London: department of health 2016.

18 Curtis L, Burns A. *Unit costs of health and social care 2015*. the University of Kent: Canterbury, 2015.

19 Sterne JAC, White IR, Carlin JB, *et al*. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009;338:b2393.

20 White IR, Horton NJ, Carpenter J, *et al*. Strategy for intention to treat analysis in randomised trials with missing outcome data. *BMJ* 2011;342:d40.

21 Faria R, Gomes M, Epstein D, *et al*. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. *Pharmacoeconomics* 2014;32:1157–70.

22 White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. *Stat Med* 2011;30:377–99.

23 Aris A, Cámara ML, Montiel J, *et al*. Ministernotomy versus median sternotomy for aortic valve replacement: a prospective, randomized study. *Ann Thorac Surg* 1999;67:1583–7.

24 Moustafa MA, Abdelsamad AA, Zakaria G, *et al*. Minimal vs median sternotomy for aortic valve replacement. *Asian Cardiovasc Thorac Annals* 2007;15:472–5.

25 Rodríguez-Caulo EA, ArantzaGuzón A, Otero-Forero J, *et al*. Quality of life after ministernotomy versus full sternotomy aortic valve replacement.

26 Vukovic PM, Milojevic P, Stojanovic I, *et al*. The role of ministernotomy in aortic valve surgery-a prospective randomized study. *J Card Surg* 2019;34:435–9.

27 National comparative audit of blood transfusion. Available: http://hospital.blood.co.uk/media/26859/nca-2011_use_of_blood_in_adult_cardiac_surgery_ report.pdf [Accessed 23 Jul 2018].

28 Hancock HC, Maier RH, Kasim AS, *et al*. Mini-sternotomy versus conventional sternotomy for aortic valve replacement. *J Am Coll Cardiol* 2019;73:2491–2.

Supplemental material
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)
BMJ Open

Supplementary Material

Study Investigators: trial site, trials unit, statistics, health economics, committees

Trial Site
The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom

Investigators
- Mr Enoch Akowuah (Chief Investigator)
- Mr Andrew Goodwin (co-Investigator)
- Professor W Andrew Owens (co-Investigator)

Research Team
- Heather Robinson
- Jonathan Broughton
- Dr Khalid Khan

Clinical Trials Unit
Durham Clinical Trials Unit, Durham University; now Newcastle Clinical Trials Unit, Newcastle University

Investigators
- Professor Helen Hancock (co-Investigator)
- Rebecca Maier (co-Investigator)

Research Team
- Andrew Thorpe
- Jennifer Wilkinson
- Dr Leanne Marsay

Statistics
Statistics Group, Wolfson Research Institute for Health and Wellbeing, Durham University

Investigator
- Dr Adetayo Kasim (co-Investigator)

Health Economics
Durham Clinical Trials Unit, Durham University; now University of Warwick

Investigator
- Professor James Mason (co-Investigator)

Committees
Data Monitoring Committee Membership
- Mr Graham Cooper (Chair)
- Mr Heyman Luckraz
- Professor Chris Rogers

Trial Steering Committee Membership
- Mr Sukumaran Nair (Chair until Sep 2014)
- Professor Gavin Murphy (Acting Chair Oct 2014 to June 2015)
- Mr Peter Braidley (Chair, from July 2015)
- Mr Paul Modi
- Mr Brendan Ellis

Table 1. Eligibility criteria

Inclusion Criteria

- Aged 18 years or older at the time of consent
- Requiring first-time, non-emergency, isolated Aortic Valve Replacement surgery
- Able and willing to provide written informed consent

Exclusion Criteria

- requiring concomitant cardiac procedure(s) including redo surgery, emergency or salvage surgery,
- only conventional median sternotomy indicated*,
- haemoglobin level < 90g/L,
- pregnant**,
- currently participating in another interventional clinical trial,
- previous cardiac surgery,
- are unable to stop currently prescribed treatment affecting clotting (e·g·, heparin, warfarin), ***
- a history of thrombophilia, thrombocytopenia or other haematological conditions that would affect participation in the trial as determined by one of the three operating surgeons,
- infective endocarditis,
- prevented from having red blood cells and blood products according to a system of beliefs (e·g· Jehovah's Witnesses),
- having any other medical, psychiatric and or social reason as determined by the consenting surgeon that precludes participation.

* patients were excluded if only conventional median sternotomy was indicated, for example in the presence of significant skeletal abnormalities like kyphosis. They were also excluded if transoesophageal echocardiography could not be performed, as this was mandatory to perform safe peripheral venous cannulation. All 3 surgeons used consistent criteria.

** in women of child bearing age (18 – 50) a pregnancy test was be performed within 14 days of surgery prior to randomisation.

***for patients in both trial arms, pre-operative antiplatelet drugs (including clopidogrel and ticagrelor), and anti-coagulants (including warfarin and heparin) were discontinued 5 days prior to surgery. These drugs were re-started following surgery at the discretion of the clinical team· The exception to this was aspirin, which was stopped 5 days prior to surgery where possible, however continuation until the day of surgery did not exclude a patient from the trial.

Figure 1. Trial recruitment by month.

Table 2. Conversion from mini-sternotomy to conventional sternotomy

Reason for conversion	Number of patients	Details
Anaesthetic emergency	**2**	• Patient became unstable as they were transferred into theatre and BP dropped – required conventional to re-stabilise • Anaphylactic reaction on induction needing CPR· Operation cancelled, patient taken to ITU· Widespread rash· Decision made the following morning to proceed to AVR (via full sternotomy)
Difficult vascular access (venous or arterial)	**9**	Venous • Femoral vessels unsuitable for cannulation • Poor venous drainage • Unable to pass venous dilators • Unable to insert pipe· Resistance felt, no back flow of blood· Femoral cannulation abandoned • Impossible to dilate femoral vein· Despite re-wiring, guide wire coiling within pelvic venous system Arterial • Difficulties cannulating femoral artery leading to haemodynamic instability • Poor access, unable to clamp aorta • Severe calcification of ascending aorta • Difficult access; aorta displaced to the left· Body habitus limited access
Intra-operative complications	**5**	• Bleeding from aortotomy site • Bleeding • Intra-operative decision to performed bypass graft to LAD • Post implant TOE showed small paravalvular leak and bleeding from aortotomy incision • Mild/moderate paravalvar leak on TOE· Required valve re-implant
TOTAL	**16**	

Table 3. Number of operations performed by Consultant Surgeon

	Mini-sternotomy group n=patients (%)	Conventional sternotomy group n=patients (%)	Total n=patients (%)
Consultant Surgeon A	58 (43·0)	58 (43··0)	116 (43·0)
Consultant Surgeon B	43 (31·9)	35 (25·9)	78 (28·9)
Consultant Surgeon C	34 (25·1)	42 (31·1)	76 (28·1)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Figure 2. Haemoglobin profiles at Baseline, during CICU stay, and day 1 to day 4 post index surgery, by group

Table 4. Analgesic use and pain scores

| Medication	Mini-sternotomy Group (135 patients) n = patients (%)	Conventional Sternotomy Group (135 patients) n = patients (%)	Total (270 patients) n = patients (%)
Analgesic use at baseline			
Buprenorphine patch	3 (2·2)	1 (0·7)	4 (1·5)
Codeine Phosphate	4 (3·0)	3 (0·7)	7 (2·6)
Dihydrocodeine Tartrate	0 (0·0)	1 (0·7)	1 (0·4)
Durogesic patch	0	1 (0·7)	1 (0·4)
Fentanyl	1 (0·7)	0 (0·0)	1 (0·4)
Gabapentin	1 (0·7)	0 (0·0)	1 (0·4)
Morphine Sulfate	0·0	1 (0·7)	1 (0·4)
Naxoproxen	1 (0·7)	0 (0·0)	1 (0·4)
Paracetamol	13 (9·6)	8 (5·9)	21 (7·8)
Tramadol Hydrochloride	0 (0·0)	2 (1·5)	2 (0·7)
At least one med at baseline	**16 (11·9)**	**12 (8·9)**	**28 (10·4)**
Analgesic use at day 2			
Buprenorphine patch	1 (0·7)	0 (0·0)	1 (0·4)
Codeine Phosphate	18 (13·3)	16 (11·9)	34 (12·6)
Dihydrocodeine Tartrate	4 (3·0)	6 (4·4)	10 (3·7)
Fentanyl	1 (0·7)	0 (0·0)	1 (0·4)
Gabapentin	1 (0·7)	0 (0·0)	1 (0·4)
Morphine Sulfate	13 (9·6)	13 (9·6)	26 (9·6)
Oramorph	1 (0·7)	1 (0·7)	2 (0·7)
Paracetamol	94 (69·6)	80 (59·3)	174 (64·4)
Pregabalin	1 (0·7)	0 (0·0)	1 (0·1)
Tramadol Hydrochloride	7 (5·2)	5 (3·7)	12 (4·4)
At least one med at day 2	**99 (73·3)**	**86 (63·7)**	**185 (68·5)**
Analgesic use at day 3			
Buprenorphine patch	1 (0·7)	0 (0·0)	1 (0·4)
Codeine Phosphate	14 (10·4)	21 (15·6)	35 (13·0)
Dihydrocodeine Tartrate	4 (3·0)	7 (5·2)	11 (4·1)
Fentanyl	0 (0·0)	1 (0·7)	1 (0·4)
Gabapentin	1 (0·7)	1 (0·7)	2 (0·7)
Ibuprofen	0	1 (0·7)	1 (0·4)
Morphine Sulfate	6 (4·4)	1 (0·7)	7 (2·6)
Nefopam Hydrochloride	0	1 (0·7)	1 (0·4)
Oramorph	0	3 (2·2)	3 (1·1)
Paracetamol	89 (65·9)	99 (73·3)	188 (69·6)
Pregabalin	1 (0·7)	0 (0·0)	1 (0·4)
Tramadol Hydrochloride	8 (5·9)	3 (2·2)	11 (4·1)
At least one med at day 3	**90 (66·7)**	**101 (74·8)**	**191 (70·7)**
Analgesic use at Day 4			
Buprenorphine patch	1 (0·7)	0 (0·0)	1 (0·4)
Codeine Phosphate	15 (11·1)	15 (11·1)	30 (11·1)
Dihydrocodeine Tartrate	4 (3·0)	9 (6·7)	13 (4·8)
Fentanyl	1 (0·7)	1 (0·7)	2 (0·7)
Gabapentin	1 (0·7)	1 (0·7)	2 (0·7)
Ibuprofen	0 (0·0)	1 (0·7)	1 (0·4)
Paracetamol	86 (63·7)	75 (55·6)	161 (59·6)
Morphine Sulfate	1 (0·7)	2 (1·5)	3 (1·1)
Pregabalin	1 (0·7)	0 (0·0)	1 (0·4)
Tramadol Hydrochloride	3 (2·2)	3 (2·2)	6 (2·2)
At least one med at day 4	**88 (65·2)**	**81 (60·0)**	**169 (62·6)**
Analgesic use at Week 6			
Buprenorphine Patch	3 (2·2)	0 (0·0)	3 (1·1)
Codeine Phosphate	7 (5·1)	5 (3·7)	12 (4·5)
Dihydrocodeine Tartrate	1 (0·7)	3 (2·2)	4 (1·5)
Fentanyl	1 (0·7)	0 (0·0)	1 (0·4)
Gabapentin	2 (1·5)	1 (0·7)	3 (1·1)
Ibuprofen	0 (0·0)	1 (0·7)	1 (0·4)
Morphine Sulfate	0 (0·0)	1 (0·7)	1 (0·4)
Paracetamol	35 (25·9)	38 (28·1)	73 (27·0)
Pregabalin	1 (0·7)	0 (0·0)	1 (0·4)
Tramadol Hydrochloride	2 (1·5)	2 (1·5)	4 (1·5)
At least one med at week 6	**41 (30·4)**	**41 (30·4)**	**82 (30·4)**
Analgesic use at Week 12			
Buprenorphine Patch	3 (2·2)	0 (0·0)	3 (1·1)
Codeine Phosphate	7 (5·2)	4 (3·0)	11 (4·1)

Dihyrocodeine Tartrate	0(0·0)	1(0·7)	1(0·4)
Gabapentin	2(1·5)	0(0·0)	2(0·7)
Ibuprofen	1(0·7)	0(0·0)	1(0·4)
Morphine Sulfate	1(0·7)	1(0·7)	2(0·7)
Naproxen	1(0·7)	0(0·0)	1(0·4)
Paracetamol	19(14·1)	20(14·8)	39(14·4)
Tramadol Hydrochloride	1(0·7)	1(0·7)	2(0·7)
At least one med at week 12	**23(17·0)**	**22(16·3)**	**45(16·7)**

	Mini-sternotomy Group (n=135 patients)	Conventional sternotomy group (n=135)
Baseline pain score		
n	128*	130*
Mean± SD	1·3 ± 2·1	0·9 ± 1·9
(min-max)	0 - 10	0 - 8
Day 2 pain score**		
n	123*	126*
Mean± SD	3·4 ± 2·4	3·7 ± 2·7
(min-max)	0 - 10	0 - 10
Day 3 pain score		
n	120*	129*
Mean± SD	2·8 ± 2·5	2·7 ± 2·3
(min-max)	0 - 9	0 - 8
Day 4 pain score		
n	116*	120*
Mean± SD	2·5 ± 2·2	2·1 ± 2·3
(min-max)	0 - 8	0 - 10
6 week pain score		
n	112*	118*
Mean± SD	1·5 ± 1·9	1·2 ± 1·8
(min-max)	0 - 8	0 - 8
12 week pain score		
n	128*	122*
Mean± SD	1·1 ± 1·9	1·0 ± 1·7
(min-max)	0 - 8	0 – 6

*Pain scores were assessed wherever possible
**Assessment on Day 2 was conducted with the patient blinded to their surgical allocation

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Table 5. Adverse Events

Adverse Event	Mini-sternotomy Group n = patients (%)	Conventional Sternotomy Group n = patients (%)	Total n = patients (%)
Death			
In hospital	0/135 (0·0)	0/135 (0·0)	0/270 (0·0)
12 weeks	2/135 (1·5)	2/135 (1·5)	4/270 (1·5)
Stroke			
In hospital	3/135 (3·0)	1/135 (0·7)	4/270 (1·5)
12 weeks	4/135 (3·0)	1/135 (0·7)	5/270 (1·9)
Transient Ischaemic Attack			
In hospital	0/135 (0·0)	1/135 (0·7)	1/270 (0·4)
12 weeks	3/135 (2·2)	1/135 (0·7)	4/270 (1·5)
Renal failure			
In hospital	4/135 (2·3)	0/135 (0·0)	4/270 (1·5)
12 weeks	4/135 (2·3)	1/135 (0·7)	5/270 (1·9)
Atrial Arrhythmias			
In hospital	51/135 (37·8)	42/135 (31·1)	93/270 (34·4)
12 weeks	61/135 (45·2)	51/135 (37·8)	112/270 (41·5)
Ventricular Arrhythmias			
In hospital	2/135 (1·5)	2/135 (1·5)	4/270 (1·5)
12 weeks	2/135 (1·5)	2/135 (1·5)	4/270 (1·5)
Pericardial Effusion			
In hospital	4/135 (2·3)	1/135 (0·7)	5/270 (1·9)
12 weeks	9/135 (6·7)	6/135 (4·4)	15/270 (5·6)
Pulmonary Embolism			
In hospital	0/135 (0·0)	0/135 (0·0)	0/270 (0·0)
12 weeks	0/135 (0·0)	2/135 (1·5)	2/270 (0·7)
Chest Infection			
In hospital	7/135 (5·2)	10/135 (7·4)	17/270 (6·3)
12 weeks	18/135 (13·3)	26/135 (19·3)	44/270 (16·3)
Sternal wound infection			
In hospital	3/135 (2·2)	1/135 (0·7)	4/270 (1·5)
12 weeks	11/135 (8·1)	3/135 (2·2)	14/270 (5·2)
Re-operation for bleeding	3/135 (2·2)	5/135 (3·7)	8/270 (3·0)

Table 6. Health status, resource use and cost (complete cases)

	Conventional [C]			Mini-sternotomy [M]			[M]-[C][1]	
	mean	(SD)	N	mean	(SD)	N	mean	(95%CI)
Health status[2]								
EQ-5D Baseline	0·764	0·245	130	0·763	0·235	128	-0·001	(-0·060 to 0·057)
EQ-5D 2 days	0·349	0·349	133	0·353	0·291	128	0·004	(-0·074 to 0·082)
EQ-5D 6 weeks	0·798	0·194	118	0·751	0·221	112	-0·048	(-0·101 to 0·006)
EQ-5D 12 weeks	0·838	0·207	124	0·782	0·248	127	-0·056	(-0·112 to 0·001)
EQ-5D AUC (0-12 weeks)	0·162	0·041	105	0·153	0·040	98	-0·009	(-0·020 to 0·002)
Resource use								
Index Admission								
Length of stay (d)[3]	8·26	4·28	135	9·29	7·88	135	1·03	(-0·48 to 2·54)
CICU (d)	1·21	0·99	135	1·61	5·52	135	0·39	(-0·55 to 1·34)
HDU (d)	1·27	1·52	135	1·60	1·75	135	0·33	(-0·07 to 0·72)
Cardiac ward (d)	5·67	3·52	135	5·70	3·18	135	0·03	(-0·77 to 0·83)
Stroke ward (d)	0·03	0·34	135	0·11	1·00	135	0·08	(-0·10 to 0·26)
Time in first surgery (h)	2·24	0·51	135	2·98	0·69	135	0·74	(0·60 to 0·89)
Time in further surgery (h)[4]	0·08	0·34	135	0·03	0·17	135	-0·05	(-0·11 to 0·02)
Time in surgery (h)[4]	2·32	0·63	135	3·01	0·71	135	0·69	(0·53 to 0·85)
RBC (u)[4]	0·59	1·45	135	0·55	1·28	135	-0·04	(-0·37 to 0·28)
FFP (u)[4]	0·57	1·43	135	0·34	1·21	135	-0·23	(-0·55 to 0·09)
Platelets (u)[4]	0·22	0·64	135	0·12	0·46	135	-0·10	(-0·24 to 0·03)
Cryoprecipitate (u)[4]	0·01	0·09	135	0·00	0·00	135	-0·01	(-0·02 to 0·01)
Post discharge contacts								
GP surgery	1·47	1·52	129	1·40	1·32	131	-0·07	(-0·41 to 0·28)
GP home	0·09	0·32	129	0·19	0·56	131	0·10	(-0·01 to 0·21)
GP telephone	0·12	0·45	129	0·15	0·63	131	0·03	(-0·10 to 0·16)
Nurse surgery	1·38	2·56	129	2·07	3·54	131	0·69	(-0·06 to 1·44)
Nurse home	0·43	1·30	129	0·56	1·87	131	0·12	(-0·27 to 0·51)
Nurse telephone	0·05	0·25	129	0·04	0·26	131	-0·01	(-0·07 to 0·05)
Outpatient hospital	0·40	0·78	129	0·57	1·98	131	0·17	(-0·20 to 0·53)
Inpatient hospital	0·30	0·68	129	0·27	0·60	131	-0·03	(-0·18 to 0·13)
Inpatient hospital (d)	2·09	7·79	129	1·09	2·69	131	-1·00	(-2·42 to 0·42)
Total Contacts	4·29	3·53	129	5·47	4·90	131	1·18	(0·14 to 2·22)
Cost[5]								
Cost of index admission	7674	2055	135	8815	4517	135	1140	(303 to 1977)
Cost post discharge	824	2485	129	547	925	131	-277	(-734 to 180)
Cost	8527	3558	129	9274	4542	131	746	(-245 to 1737)

1 OLS regression-estimated means and 95% confidence intervals
2 EQ-5D-3L index score
3 Length stay by ward does not sum to length of stay due to theatre and transit time, and rounding
4 Item includes index and post-discharge usage
5 Resource items were costed using national reference costs except for the index procedures which were costed by South Tees Hospitals NHS Foundation Trust

Table 7. ICU Length of Stay, Fitness for Discharge and Hospital Length of Stay

	Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)
ICU stay (days)		
n	135	135
Mean ± SD	1·9 ± 5·8	1·3 ± 1·1
Min-Max	0 - 64*	0 - 7
Fitness for discharge (days)		
n	129**	133**
Mean ± SD	6·5 ± 3·7	6·3 ± 3·2
Min - Max	3 - 36	3 - 31
Post-operative length of stay (days)		
n	135	135
Mean ± SD	7·4 ± 7·5	6·3 ± 3·1
Min - Max	3 - 79	3 - 31

*3 patients in the mini-sternotomy group were in ICU for more than 7 days· Excluding these patients, the range would have been 0-5 days for the mini-sternotomy group.

**Fitness for discharge was assessed by the surgical and physiotherapy teams. For 6 patients in the mini-sternotomy group and 2 patients in the conventional sternotomy group this was not possible due staff availability at the point of discharge.

Table 8. Pulmonary Function Tests

		Mini-sternotomy group (n=135)	Conventional sternotomy group (n=135)	Mean Difference (95% CI; p value)
FEV1				
Baseline				
	n	123*	123*	
	Mean ± SD	2196·2 ± 712·2	2207·7 ± 748·2	-15·4 (-169·2,138·4)
	Min - Max	1000- 4340	1020-4090	
Day 4				
	n	105*	110*	
	Mean ± SD	1122·6 ± 433·0	1320·7 ± 523·5	-171·3** (-265·3,-77·2; p=0·0004)
	Min - Max	99-2400	76-2910	
6 weeks				
	n	106*	97*	
	Mean ± SD	1962·0 ± 468·7	2018·1 ± 662·8	-7·3** (-104·3,89·6)
	Min - Max	650-3570	870-3570	
FVC				
Baseline				
	n	123*	123*	
	Mean ± SD	2908·5 ± 926·4	2929·2 ± 955·7	-31·6 (-238·8,175·7)
	Min - Max	1250-6060	1200-5650	
Day 4				
	n	105*	110*	
	Mean ± SD	1478·9 ± 583·3	1697·5 ± 706·8	-129·7** (-259·2,-0·1; p=0·0498)
	Min - Max	139-2910	109-3920	
6 weeks				
	n	106*	97*	
	Mean ± SD	2529·4 ± 824·0	2615·9 ± 864·0	-36·0** (-173·2,101·2)
	Min - Max	1180-4760	1000-4840	

*It was not possible for all patients to complete pulmonary function tests
**After adjusting for randomisation factors and baseline data